Cisplatin+Pembrolizumab+RT in Vulvar Cancer
Cisplatin+Pembrolizumab+RT in Vulvar Cancer
Active, not recruiting · NCT04430699 · Registry updated 2026-05-05Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Cisplatin+Pembrolizumab+RT in Vulvar Cancer | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, female reproductive system disorder, female reproductive system neoplasm, neoplasm, vulva cancer, vulvar disease, vulvar squamous cell carcinoma | Active, not recruiting | Phase 2 | 2026-05-05 | NCT04430699 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Massachusetts General Hospital | 758 |
| Merck Sharp & Dohme LLC | 650 |
2 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Beth Israel Deaconess Medical Center | Boston | United States | 462 |
| Massachusetts General Hospital Cancer Center | Boston | United States | 178 |